Skip Ribbon Commands
Skip to main content

News

 

 

Launch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacyhttps://www.terumo-europe.com/en-emea/news/launch-of-new-multi-center-study-investigating-resorbable-drug-eluting-microspheres-safety-and-efficacyLaunch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacy3/10/2024 11:00:00 PM<p><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;">​</span><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;">Terumo Europe N.V. announces the launch of the BIOPEARL-ONE study, a new multi-center post market clinical trial: BioPearl<sup>TM</sup> microspheres are loaded with doxorubicin to treat patients with unresectable hepatocellular carcinoma (HCC). A prospective, single arm, multi-centre post-market follow-up study is intended to assess the safety and efficacy of BioPearl<sup>TM</sup> microspheres loaded with doxorubicin in the treatment of patients with unresectable HCC. </span>​<br></p>
Terumo expands global presence with new subsidiary in South-Africahttps://www.terumo-europe.com/en-emea/news/terumo-expands-global-presence-with-new-subsidiary-in-south-africaTerumo expands global presence with new subsidiary in South-Africa11/29/2023 11:00:00 PM<p>Terumo Corporation (TSE: 4543) today announced the establishment of Terumo South Africa (Pty) Ltd. (Terumo South Africa), its newest subsidiary in South-Africa. This strategic move represents a significant milestone in the company’s continued commitment to expanding its global footprint and strengthening its presence in key growing markets.​<br></p>
ANGIO-SEAL™ VIP & FEMOSEAL™ VASCULAR CLOSURE DEVICES SECURED CE CERTIFICATE UNDER THE NEW MEDICAL DEVICE REGULATIONhttps://www.terumo-europe.com/en-emea/news/angio-seal™-vip-femoseal™-vascular-closure-devices-secured-ce-certificate-under-the-new-medical-device-regulationANGIO-SEAL™ VIP & FEMOSEAL™ VASCULAR CLOSURE DEVICES SECURED CE CERTIFICATE UNDER THE NEW MEDICAL DEVICE REGULATION10/3/2023 10:00:00 PM<p>Terumo (TSE: 4543) is proud to announce that both of our Vascular Closure Devices, Angio-Seal™ VIP & Femoseal™, received the EU MDR certifications.​<br></p>
Terumo Group Associates Celebrate Terumo Patient’s Day 2023https://www.terumo-europe.com/en-emea/terumo-group-associates-celebrate-terumo-patient’s-day-2023Terumo Group Associates Celebrate Terumo Patient’s Day 20239/14/2023 10:00:00 PM<p>Terumo Corporation (TSE: 4543) today held “Terumo Patient’s Day 2023” to connect with Terumo’s Group Mission of “Contributing to Society through Healthcare”, and for each associate to reconfirm their day-to-day contribution at work ultimately leads to the well-being of patients.​<br></p>
Terumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Companyhttps://www.terumo-europe.com/en-emea/news/terumo-to-construct-a-new-manufacturing-facility-at-its-kofu-factory-for-the-medical-care-solutions-companyTerumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Company5/14/2023 10:00:00 PM<p>52.2 Billion JPY Capital Investment to Strengthen the Production Capability to Meet the Growing Global Demands​<br></p>
Ultimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCIhttps://www.terumo-europe.com/en-emea/news/ultimaster-nagomi™-mdr-certification-and-launch-of-large-scale-post-market-study-investigating-the-new-coronary-stent-systeUltimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCI4/25/2023 10:00:00 PM<p></p>​First patient enrolled in the NAGOMI COMPLEX PMCF study <br>